David Calvet Canut։ Efdoralprin Alfa Shows Promise in Alpha 1 Antitrypsin Deficiency
David Calvet Canut, Chief Financial Officer at Rudder Marine Services and Ship Repairs S.L, shared a post on LinkedIn:
”A potential breakthrough for Alpha-1 Antitrypsin Deficiency (AATD) has emerged from Sanofi’s Phase 2 ElevAATe clinical trial.
The investigational treatment, efdoralprin alfa, has shown promising results for adults living with pulmonary emphysema caused by AATD.
Unlike current therapies that rely on donated plasma, efdoralprin alfa is a recombinant protein produced in the laboratory, designed to mimic the natural AAT protein that protects the lungs from inflammatory damage.
This could represent a significant advancement towards a more sustainable, supply-independent treatment option.
Key findings from the ElevAATe trial include:
- Patients achieved normal, stable levels of functional AAT protein, significantly higher than those seen with standard plasma-derived treatment.
- A greater proportion of days were spent at protective protein levels.
- The treatment was well tolerated, with a safety profile comparable to existing therapies.
- It is effective when administered every three to four weeks, potentially offering a more convenient treatment schedule.
Dr. Igor Barjaktarevic, lead investigator at UCLA, noted that achieving normal AAT levels without relying on plasma donations ‘would be a very positive change’ for patients living with Alpha-1.
Efdoralprin alfa has already received both Fast Track and Orphan Drug designations from the FDA, indicating the unmet need this treatment aims to address.
A long-term safety follow-up study (ElevAATe OLE) is now underway.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 12:34Stijn Wigerinck: A Practical Roadmap for Eosinophilia and Hypereosinophilia
-
Sep 5, 2026, 11:51Alejandro González Veliz: Why Secondary Prevention Matters After PCI
-
Sep 5, 2026, 11:39Julie Rayes: Sepsis Rewrites the Role of Mast Cells in Thrombosis
-
Sep 5, 2026, 11:30Shirley D’Sa: Chemoimmunotherapy in Cold Agglutinin Disease and WM-Associated CAS
-
Sep 5, 2026, 11:29Dilini Christina Ranasinghe: An Exception to the ‘Universal Donor’ – Bombay (Oh)
-
Sep 5, 2026, 11:10Amanda Stahl: Integrating Psychosocial Care Into Comprehensive Hemophilia Treatment
-
Sep 5, 2026, 10:23Danny Hsu: Honouring Rob Bird’s Career and Impact in Haematology
-
Sep 5, 2026, 10:12Wolfgang Miesbach: Can Emicizumab Be Used During Breastfeeding?
-
Sep 5, 2026, 09:52Lorena Arranz: Shaping the Future of Hematology with EHA 2027